Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Y K Loke; R Ho; M Smith; O Wong; M Sandhu; W Sage; S Singh

doi:10.1111/jcpt.12080

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Y K Loke, R Ho, M Smith, O Wong, M Sandhu, W Sage, S Singh

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

Original language	English
Pages (from-to)	405-415
Number of pages	11
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	38
Issue number	5
DOIs	https://doi.org/10.1111/jcpt.12080
Publication status	Published - Oct 2013

Keywords

5-alpha Reductase Inhibitors
Azasteroids
Cardiovascular Diseases
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Humans
Male
Prostatic Diseases
Randomized Controlled Trials as Topic
Risk

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jcpt.12080

Cite this

@article{5d61dcdbbde84d0b8df7de9fa4cd2193,

title = "Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride",

abstract = "A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.",

keywords = "5-alpha Reductase Inhibitors, Azasteroids, Cardiovascular Diseases, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Humans, Male, Prostatic Diseases, Randomized Controlled Trials as Topic, Risk",

author = "Loke, {Y K} and R Ho and M Smith and O Wong and M Sandhu and W Sage and S Singh",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = oct,

doi = "10.1111/jcpt.12080",

language = "English",

volume = "38",

pages = "405--415",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

AU - Loke, Y K

AU - Ho, R

AU - Smith, M

AU - Wong, O

AU - Sandhu, M

AU - Sage, W

AU - Singh, S

PY - 2013/10

Y1 - 2013/10

N2 - A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

AB - A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

KW - 5-alpha Reductase Inhibitors

KW - Azasteroids

KW - Cardiovascular Diseases

KW - Double-Blind Method

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Male

KW - Prostatic Diseases

KW - Randomized Controlled Trials as Topic

KW - Risk

U2 - 10.1111/jcpt.12080

DO - 10.1111/jcpt.12080

M3 - Article

C2 - 23815285

VL - 38

SP - 405

EP - 415

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 5

ER -